Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03894618` - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas	Phase 1
Terminated	`NCT02042885` - A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03357757` - Avelumab With Valproic Acid in Virus-associated Cancer	Phase 2
Recruiting	`NCT03221400` - PEN-866 in Patients With Advanced Solid Malignancies	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1

Terminated

NCT02042885 - A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Phase 1/Phase 2

Active, not recruiting

NCT03357757 - Avelumab With Valproic Acid in Virus-associated Cancer

Phase 2

Recruiting

NCT03221400 - PEN-866 in Patients With Advanced Solid Malignancies

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01639625
Study type	Interventional
Source	Laboratorio Elea S.A.C.I.F. y A.
Contact
Status	Completed
Phase	Phase 2
Start date	May 2011
Completion date	January 2016

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms